Imbalance of the protease-antiprotease system against the background of chronic obstructive pulmonary disease in combination with ischemic heart disease

Authors

DOI:

https://doi.org/10.14739/2310-1237.2023.2.278133

Keywords:

ischemic heart disease, chronic obstructive pulmonary disease, matrix metalloproteinase 9, tissue inhibitor of metalloproteinases, fibrosis

Abstract

The aim of the study: to evaluate the clinical value of the violation of the expression level of MMP-9 and TIMP against the background of chronic obstructive pulmonary disease (COPD) in combination with ischemic heart disease (IHD).

Materials and methods. In accordance with the set goal of the study, 26 people with COPD + IHD and 22 practically healthy people were under observation. The average age of patients was 56.68 ± 1.21 years; 76.92 % were men. In the control group, the average age was 54.37 ± 1.84 years, 72.73 % were men. The object of the study was ischemic heart disease: angina pectoris. Research methods: external respiration function study, six minute walk test, determination of heart rate variability, the concentration of MMP-9 and TIMP in blood serum was determined by the method of solid-phase enzyme immunoassay.

Results. The analysis of the level of expression of proteases and its inhibitor shows that patients with comorbid IHD on the background of COPD demonstrated 8.11 times higher activity of MMP-9 (p < 0.05) compared to a cohort of practically healthy people. Indicators of TIMP activity in patients with IHD on the background of COPD are 1.46 ± 0.03 μg/ml, which is statistically significantly lower by 53.21 % (p < 0.05) compared to healthy people (3.12 ± 0.01 μg/ml). The presence of reliable correlations between the MMP-9 level and the FEV1 indicator (r = -0.67, p < 0.05), the LF/HF parameter (r = -0.74, p < 0.05) indicates, that when the level of expression of MMP-9 is elevated, there is a more pronounced violation of the function of external respiration and a shift in the sympatho-parasympathetic balance in the direction of sympathetic activation and a decrease in vagal tone in heart rate modulation.

The analysis of the meeting frequency with the analysis of conjugation tables showed that in persons in the upper quartile of MMP-9, prognostically negative parameters of the function of external breathing – an isolated decrease in the Tifno index (χ2 = 5.2 at p = 0.03), as well as the expressiveness of shortness of breath – were recorded more often ≥6 points on the Borg scale when assessing exercise tolerance during the 6-minute walk test (χ2 = 7.3 at p = 0.02).

Conclusions. The obtained data demonstrate that patients with IHD on the background of COPD have a pronounced proteolytic imbalance and disruption of fibrotic processes compared to practically healthy individuals.

Author Biography

O. O. Kraidashenko, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, Postgraduate student of the Department of Internal Diseases 3

References

  1. Wise, R. A., Anderson, J. A., Amarenco, P., Cowans, N. J., Crim, C., Denvir, M. A., Gomez, C. R., Jones, M. P., Morris, A., Niewoehner, D., & Yates, J. C. (2020). Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial. Clinical trials, 17(4), 430-436. https://doi.org/10.1177/1740774520920897
  2. Güder, G., & Störk, S. (2019). COPD and heart failure: differential diagnosis and comorbidity. COPD und Herzinsuffizienz: Differenzialdiagnose und Komorbidität. Herz, 44(6), 502-508. https://doi.org/10.1007/s00059-019-4814-7
  3. Asanov, E. O. (2018). Yakist zhyttia khvorykh pokhyloho viku z KhOZL [Quality of life of elderly patients with COPD]. Medicni perspektivi, 23, (2Part1), 76. [in Ukrainian].
  4. Gashynova, K. Yu. (2018). Khronichne obstruktyvne zakhvoriuvannia lehen (KhOZL): vplyv kliniko-anamnestychnykh, antropometrychnykh ta funktsionalnykh kharakterystyk na riven a-1-antytrypsynu (AAT) v syrovattsi krovi stabilnykh khvorykh [Chronic obstructive pulmonary disease (COPD): influence of clinical and anamnestic, anthropometric and functional characteristics on the level of α-1-antitrypsin (AAT) in blood serum of stable patients]. Medicni perspektivi, 23(3Part1). 52-60. [in Ukrainian]. https://doi.org/10.26641/2307-0404.2018.3(part1).142334
  5. Nandi, S. S., Katsurada, K., Sharma, N. M., Anderson, D. R., Mahata, S. K., & Patel, K. P. (2020). MMP9 inhibition increases autophagic flux in chronic heart failure. American journal of physiology. Heart and circulatory physiology, 319(6), H1414-H1437. https://doi.org/10.1152/ajpheart.00032.2020
  6. Yadav, S. K., Kambis, T. N., Kar, S., Park, S. Y., & Mishra, P. K. (2020). MMP9 mediates acute hyperglycemia-induced human cardiac stem cell death by upregulating apoptosis and pyroptosis in vitro. Cell death & disease, 11(3), 186. https://doi.org/10.1038/s41419-020-2367-6
  7. Liu, N., Wang, X., Wu, H., Lv, X., Xie, H., Guo, Z., Wang, J., Dou, G., Zhang, C., & Sun, M. (2021). Computational study of effective matrix metalloproteinase 9 (MMP9) targeting natural inhibitors. Aging, 13(19), 22867-22882. https://doi.org/10.18632/aging.203581
  8. Zheng, Y. F., Zhu, H. Y., Wang, W., Hu, J. J., Bao, T. P., & Tian, Z. F. (2021). Role of the LRP1-pPyk2-MMP9 pathway in hyperoxia-induced lung injury in neonatal rats. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 23(12), 1289-1294. https://doi.org/10.7499/j.issn.1008-8830.2108125
  9. Wang, C., Li, Q., Yang, H., Gao, C., Du, Q., Zhang, C., Zhu, L., & Li, Q. (2020). MMP9, CXCR1, TLR6, and MPO participant in the progression of coronary artery disease. Journal of cellular physiology, 235(11), 8283-8292. https://doi.org/10.1002/jcp.29485
  10. Yosef, G., Hayun, H., & Papo, N. (2021). Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy. The Biochemical journal, 478(5), 1139-1157. https://doi.org/10.1042/BCJ20200628
  11. Nishikai-Yan Shen, T., Kado, M., Hagiwara, H., Fujimura, S., Mizuno, H., & Tanaka, R. (2021). MMP9 secreted from mononuclear cell quality and quantity culture mediates STAT3 phosphorylation and fibroblast migration in wounds. Regenerative therapy, 18, 464-471. https://doi.org/10.1016/j.reth.2021.10.003
  12. Li, T., Li, X., Liu, X., Yang, J., & Ma, C. (2021). The elevated expression of TLR4 and MMP9 in human abdominal aortic aneurysm tissues and its implication. BMC cardiovascular disorders, 21(1), 378. https://doi.org/10.1186/s12872-021-02193-1
  13. Luo, X., Wu, J., & Wu, G. (2021). PPARγ activation suppresses the expression of MMP9 by downregulating NF-κB post intracerebral hemorrhage. Neuroscience letters, 752, 135770. https://doi.org/10.1016/j.neulet.2021.135770
  14. Fang, X., Chen, J., Wang, W., Feng, G., Li, X., Zhang, X., Zhang, Y., Zhang, J., Xu, Z., Tai, J., & Ni, X. (2020). Matrix metalloproteinase 9 (MMP9) level and MMP9 -1562C>T in patients with obstructive sleep apnea: a systematic review and meta-analysis of case-control studies. Sleep medicine, 67, 110-119. https://doi.org/10.1016/j.sleep.2019.11.1247
  15. Wu, L., Wang, X., He, X., Li, Q., Hua, Q., Liu, R., & Qiu, Z. (2022). MMP9 Expression Correlates With Cisplatin Resistance in Small Cell Lung Cancer Patients. Frontiers in pharmacology, 13, 868203. https://doi.org/10.3389/fphar.2022.868203
  16. Liang, X., He, W., Zhang, H., Luo, D., Zhang, Z., Liu, A., Wang, J., & Huang, H. (2021). Inflammatory Cells Accelerated Carotid Artery Calcification via MMP9: Evidences From Single-Cell Analysis. Frontiers in cardiovascular medicine, 8, 766613. https://doi.org/10.3389/fcvm.2021.766613
  17. Li, Y., Lu, X., Li, W., Shi, Z., Du, W., Xu, H., Liu, Z., & Wu, Y. (2022). The circRERE/miR-144-3p/TLR2/MMP9 signaling axis in COPD pulmonary monocytes promotes the EMT of pulmonary epithelial cells. Biochemical and biophysical research communications, 625, 1-8. https://doi.org/10.1016/j.bbrc.2022.07.119
  18. Wells, J. M., Parker, M. M., Oster, R. A., Bowler, R. P., Dransfield, M. T., Bhatt, S. P., Cho, M. H., Kim, V., Curtis, J. L., Martinez, F. J., Paine, R., 3rd, O'Neal, W., Labaki, W. W., Kaner, R. J., Barjaktarevic, I., Han, M. K., Silverman, E. K., Crapo, J. D., Barr, R. G., Woodruff, P., … SPIROMICS and COPDGene Investigators (2018). Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene. JCI insight, 3(22), e123614. https://doi.org/10.1172/jci.insight.123614
  19. Li, H., Shi, K., Zhao, Y., Du, J., Hu, D., & Liu, Z. (2020). TIMP-1 and MMP-9 expressions in COPD patients complicated with spontaneous pneumothorax and their correlations with treatment outcomes. Pakistan journal of medical sciences, 36(2), 192-197. https://doi.org/10.12669/pjms.36.2.1244
  20. Tiede, S. L., Wassenberg, M., Christ, K., Schermuly, R. T., Seeger, W., Grimminger, F., Ghofrani, H. A., & Gall, H. (2016). Biomarkers of tissue remodeling predict survival in patients with pulmonary hypertension. International journal of cardiology, 223, 821-826. https://doi.org/10.1016/j.ijcard.2016.08.240
  21. Suzan, V., Yavuzer, H., Bag Soytas, R., Bektan Kanat, B., Arman, P., Emiroglu Gedik, T., Unal, D., Atar, O., Bolayirli, I. M., & Doventas, A. (2021). The relationship between primary sarcopenia and SARC-F, serum MMP9, TIMP1 levels, and MMP9/TIMP1 ratio in the geriatric patients. European geriatric medicine, 12(6), 1229-1235. https://doi.org/10.1007/s41999-021-00519-y
  22. Lin, Y., Huang, H., Yu, Y., Zhu, F., Xiao, W., Yang, Z., Shao, L., & Shen, Z. (2021). Long non-coding RNA RP11-465L10.10 promotes vascular smooth muscle cells phenotype switching and MMP9 expression via the NF-κB pathway. Annals of translational medicine, 9(24), 1776. https://doi.org/10.21037/atm-21-6402
  23. Gong, W., Ma, Y., Li, A., Shi, H., & Nie, S. (2018). Trimetazidine suppresses oxidative stress, inhibits MMP-2 and MMP-9 expression, and prevents cardiac rupture in mice with myocardial infarction. Cardiovascular therapeutics, 36(5), e12460. https://doi.org/10.1111/1755-5922.12460

Downloads

Published

2023-08-30

How to Cite

1.
Kraidashenko OO. Imbalance of the protease-antiprotease system against the background of chronic obstructive pulmonary disease in combination with ischemic heart disease. Pathologia [Internet]. 2023Aug.30 [cited 2026May28];20(2):182-8. Available from: https://pat.zsmu.edu.ua/article/view/278133

Issue

Vol. 20 No. 2 (2023)

Section

Original research

License

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Лицензия Creative Commons